

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
157th Meeting of the Vaccines and Related Biological Products Advisory
Committee
FDA White Oak Campus, Building 31, Great Room
Salon B & C
Silver Spring, MD
October 9, 2019

AGENDA

Meeting Link: <https://collaboration.fda.gov/vrbpac100919/>

Topic I: Presentation of the Laboratory of Hepatitis Viruses (LHV) and the Laboratory of Vector-Borne Viral Diseases (LVVD), Division of Viral Products (DVP), Office of Vaccines Research and Review (OVR), Center for Biologics Evaluation and Research (CBER)

Topic II: Strain Selection for the 2020 Southern Hemisphere Influenza Season

Note: Committee members to participate via teleconference

Time	Presentation/Presenter
8:30 AM	<p><u>Opening Remarks: Call to Order, Introduction of Committee</u> Hana El Sahly, M.D. Chair, VRBPAC</p> <p><u>Administrative Announcements, Conflict of Interest Statement</u> Serina Hunter-Thomas, M.S.A., R.N. Designated Federal Officer, VRBPAC CBER, FDA</p>
9:00 AM	<p><u>Overview of Research/Site Visit Process, CBER</u> (15 min.) Carolyn Wilson, Ph.D. Associate Director for Research CBER/FDA</p>
9:15 AM	<p><u>Overview of the Laboratories of Hepatitis Viruses & Vector-Borne Viral Diseases and the Division of Viral Products/Office of Vaccines Research and Review</u> (20 min.) Jerry Weir, Ph.D. Director, Division of Viral Products Office of Vaccines Research and Review</p>
9:35 AM	<p>Break (10 min.)</p>
9:45 AM	<p>Open Public Hearing (15 min.)</p>

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
157th Meeting of the Vaccines and Related Biological Products Advisory
Committee
FDA White Oak Campus, Building 31, Great Room
Salon B & C
Silver Spring, MD
October 9, 2019

AGENDA

10:00 AM	Closed Session (5-minute transition)
10:05 AM	<u>Committee Discussion, Recommendations and Vote (Topic I)</u> (55 min.)
	Topic II: Strain Selection for the 2020 Southern Hemisphere Influenza Season
11:00 AM	<u>Introduction and Presentation of Questions: Influenza Virus Vaccine Strain Selection – 2020 Southern Hemisphere</u> Jerry Weir, Ph.D. (30 min.) Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA
11:30 AM	<u>Global Surveillance and Virus Characterization</u> (75 min.) David Wentworth, Ph.D. Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza Chief, Virology Surveillance and Diagnosis Branch Influenza Division, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention
12:45 PM	Lunch Break (45 minutes)
1:30 PM	Open Public Hearing (45 minutes)
2:15 PM	Committee Discussion, Voting and Recommendations
3:30 PM	Adjourn Meeting